Daptomycin is used in the treatment of certain infections caused by Gram-positive organisms. Daptomycin’s distinct mechanism of action means that it may be useful in treating infections caused by multi-resistant bacteria.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>PACKAGE</th>
<th>STRENGTH</th>
<th>SIZE</th>
<th>PACK SIZE</th>
<th>CODE#</th>
<th>CONC.</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAPTOmyCiN FOR INjeCTION</td>
<td>VIAl</td>
<td>500 MG</td>
<td>10 ML</td>
<td>1 x 10</td>
<td>DPT-02</td>
<td>5MG/ML</td>
</tr>
</tbody>
</table>

Daptomycin is a relatively new antibacterial medication that offers a novel mechanism of action, rapid bactericidal activity, and an acceptable safety profile. Daptomycin has proven to be effective for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria, including those caused by MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-susceptible S. aureus). Daptomycin has also shown effectiveness in the treatment of right-sided infective endocarditis due to Staphylococcus aureus.

Marketed as Dapto-Inj™ and in India as DaptoXel™

Dapto-Inj.® is a registered trademark of Asepsis Pharmaceuticals, Inc.
DaptoXel™ is a trademark of Xellia Pharmaceuticals, SA

In Collaboration With:
183 Providence New London Tpk
North Stonington, CT 06359 USA
Tel: 888-608-8884
Email: info@asepsispharma.com

Marketed By:
New# 104/2, (Old# 328/6) Diwan Shahib Garden
T.T.K. Road, Royapettah, Chennai- 600-014
Tel: +91-44-2811 0002
Email: info@mediconpharma.com
Daptomycin for Injection
Lipopeptide Antibiotic

There have been numerous studies looking at the efficacy of Daptomycin. A retrospective, multicenter study was conducted in Taiwan between 12/07 and 6/09. The study included adult hospitalized patients who had received intravenous daptomycin therapy for infections caused by S. aureus. A total of 52 patients were evaluated. Infections included complicated skin and soft-tissue infections (n=14), catheter-related bacteremia (n=14), osteomyelitis and septic arthritis (n=12), endovascular infections and endocarditis (n=11), and urinary tract infections (n=1). Overall, 47 (90.4%) patients were successfully treated and their clinical symptoms were resolved. Adverse effects related to daptomycin were detected in nine patients, but none were required to discontinue daptomycin. The authors concluded the results support daptomycin as an effective and safe treatment for staphylococcal infections in Taiwanese populations.

A study was conducted comparing the efficacy of Daptomycin versus Glycopeptide agents. The aim of the study was to compare glycopeptides and daptomycin for the treatment of infections caused by MRSA or MR-CoNS. Data for 106 patients with bloodstream infections (bacteraemia or infective endocarditis) or skin and soft-tissue infections (SSTIs) were retrospectively reviewed, of which 43 were treated with daptomycin (DAP group) and 63 were treated with vancomycin or teicoplanin (GLyCO group). Patients included in the two comparison groups were homogeneous in terms of age, risk factors and clinical severity. Aetiology was mainly represented by MRSA in both groups, followed by various species of meticillin-resistant coagulase-negative staphylococci (MR-CoNS). Patients with SSTIs included in the GLyCO group had a longer mean duration of antibiotic therapy (18.2 days vs. 14.6 days; P=0.009) and a longer mean length of hospital stay (28.2 days vs. 19.6 days; P=0.01) compared with those included in the DAP group. A longer mean duration of antibiotic therapy was also observed in patients with bloodstream infections receiving glycopeptide therapy (25.6 days vs. 18 days; P=0.004). The authors concluded that the good clinical efficacy of daptomycin is associated with a more rapid resolution of the clinical syndrome and a reduced length of hospitalisation. This latter aspect may have important pharmacoeconomic implications, promoting the use of daptomycin in the clinical setting.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Daptomycin for injection and other antibacterial drugs, Daptomycin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. For additional information and the full Prescribing information visit: www.asepsispharma.com/therape-cat/114/

Asepsis Pharmaceuticals is pleased to offer Daptomycin for injection in the 500 mg dose strength. Daptomycin for injection is one of several offerings in our comprehensive hospital and critical care product portfolio.

www.asepsispharma.com ● www.mediconpharma.com